M&A Deal Summary

Pacific Biosciences of California Acquires Omniome

On July 20, 2021, Pacific Biosciences of California acquired life science company Omniome for 600M USD

Acquisition Highlights
  • This is Pacific Biosciences of California’s 1st transaction in the Life Science sector.
  • This is Pacific Biosciences of California’s largest (disclosed) transaction.
  • This is Pacific Biosciences of California’s 1st transaction in the United States.
  • This is Pacific Biosciences of California’s 1st transaction in California.

M&A Deal Summary

Date 2021-07-20
Target Omniome
Sector Life Science
Buyer(s) Pacific Biosciences of California
Deal Type Add-on Acquisition
Deal Value 600M USD
Advisor(s) Jefferies (Financial)
Wilson Sonsini Goodrich & Rosati
Cooley (Legal)

Target

Omniome

San Diego, California, United States
Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering high sequencing accuracy. The company's vision is to be the most trusted DNA sequencing platform and broadly support clinical sequencing. Omniome was formed in 2013 and is based in San Diego, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pacific Biosciences of California

Menlo Park, California, United States

Category Company
Founded 2004
Sector Life Science
DESCRIPTION

Pacific Biosciences of California, Inc. offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.


DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 3
State (California) 1 of 2
Country (United States) 1 of 3
Year (2021) 1 of 2
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-03 Circulomics

Baltimore, Maryland, United States

Circulomics is a biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows. Circulomics use micro-, nano-, and single-molecule technologies to streamline every step in the genomics workflow from sample preparation to assays and detection instruments. Circulomics was founded in 2009 and is based in Baltimore, Maryland.

Buy -